Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) compared with usual care (very low certainty).
1 finding from 1 review
Red cell transfusion requirements (mL) ( · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes risk of reoperation or repeat procedure for bleeding within 7 days compared with usual care (very low certainty).
1 finding from 1 review
Regression of PSR: change in number and size (in clock hours or in degrees of retinal circumference) of new blood vessels · children and adults with SCD and PSR
1 finding from 1 review
Development of new PSR: proliferation of blood vessels at a new area/progression of existing PSR after treatment · children and adults with SCD and PSR
1 finding from 1 review
Quality of life · children and adults with SCD and PSR
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · children and adults with SCD and PSR
1 finding from 1 review
Occurence of vitreous haemorrhage · children and adults with SCD and PSR
1 finding from 1 review
Adverse effects · children and adults with SCD and PSR
1 finding from 1 review
Apgar score less than 7 at 5 minutes · women with severe intrapartum fetal bradycardia
1 finding from 1 review
Umbilical artery pH · women with severe intrapartum fetal bradycardia
1 finding from 1 review
Abnormal FHR tracing · women with severe intrapartum fetal bradycardia
It is very uncertain whether summary of findings for IV atosiban changes abnormal FHR tracing compared with IV hexoprenaline (very low certainty).
1 finding from 1 review
Perinatal death or severe morbidity · women with severe intrapartum fetal bradycardia
Summary of findings for IV atosiban showed no clear difference in perinatal death or severe morbidity compared with IV hexoprenaline (low certainty).
1 finding from 1 review
Fetal or neonatal mortality · women with severe intrapartum fetal bradycardia
1 finding from 1 review
Caesarean section · women with severe intrapartum fetal bradycardia
Summary of findings for IV atosiban showed no clear difference in caesarean delivery compared with IV hexoprenaline (low certainty).
1 finding from 1 review
Change in 6‐minute walking distance · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
99 participants
Moderate
Exercise capacity · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
30 participants
High
Exercise capacity (change from baseline) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
30 participants
High